Acta Pharmaceutica Sinica. B最新文献_第3页

miniPROTACs: Bridging PROTACs and molecular glues with a new degron alphabet miniPROTACs：用新的degron字母连接PROTACs和分子胶

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-10-16 DOI: 10.1016/j.apsb.2026.09.011

Jin Wang

引用次数: 0

Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2– advanced breast cancer CDK4/6后抑制剂：基于serd的新型靶向组合治疗HR+/HER2晚期乳腺癌

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-07-31 DOI: 10.1016/j.apsb.2026.07.050

Yan Wang, Jiayu Wang, Binghe Xu

{"title":"Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2– advanced breast cancer","authors":"Yan Wang, Jiayu Wang, Binghe Xu","doi":"10.1016/j.apsb.2026.07.050","DOIUrl":"10.1016/j.apsb.2026.07.050","url":null,"abstract":"<div><div>The addition of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy has redefined the treatment paradigm for HR-positive, HER2-negative (HR<sup>+</sup>/HER2<sup>−</sup>) advanced breast cancer, with clear survival gains. However, resistance is almost inevitable and remains the central barrier to durable benefit. Selective estrogen receptor degraders (SERDs) have therefore moved from a later-line option to a core component of post-progression strategies aimed at targeting <em>ESR1</em> mutations and estrogen receptor (ER) pathway reactivation. Notably, oral SERDs differ substantially in ER occupancy, degradation potency, and pharmacokinetic behavior, and these differences appear to translate into distinct efficacy and toxicity profiles across studies. This review summarizes recent progress in SERD-based therapeutic strategies, with a focus on post-CDK4/6 inhibitor sequencing and biomarker-driven combination approaches. Particular attention is given to rational combinations with PI3K<em>α</em> and AKT inhibitors, HER2-directed tyrosine kinase inhibitors, and emerging targets such as FGFR, CDK2, and CDK7, as well as the growing role of liquid biopsy in guiding treatment adaptation. Together, these developments position SERD-centered strategies as a key framework for advancing mechanism-informed, precision treatment in HR<sup>+</sup>/HER2<sup>–</sup> advanced breast cancer.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6378-6394"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of anti-PEG antibodies on extravascular transport of stealth liposome: A study on interspecies differences 抗peg抗体对隐形脂质体血管外转运的影响：种间差异的研究

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-03-19 DOI: 10.1016/j.apsb.2026.03.027

Ercan Wu, Tianhao Ding, Yifei Yu, Mengyuan Liu, Jun Qian, Changyou Zhan

{"title":"Effects of anti-PEG antibodies on extravascular transport of stealth liposome: A study on interspecies differences","authors":"Ercan Wu, Tianhao Ding, Yifei Yu, Mengyuan Liu, Jun Qian, Changyou Zhan","doi":"10.1016/j.apsb.2026.03.027","DOIUrl":"10.1016/j.apsb.2026.03.027","url":null,"abstract":"<div><div>Cutaneous toxicity of stealth liposomal doxorubicin (sLip/DOX) has been attributed to the phagocytosis and extravascular transport of the liposomal carrier into skin by circulating neutrophils, which depended on the complement-mediated opsonization. As potent triggers of complement activation, anti-polyethylene glycol (PEG) antibodies may critically influence the cutaneous accumulation of liposomes, which has not been systematically investigated. Moreover, interspecies variability complicates the preclinical evaluation and prediction of liposomal toxicity. To bridge this gap, the present work evaluated the effects of anti-PEG antibody on the extravascular transport of stealth liposome (sLip) from an interspecies perspective. The study also investigated how anti-PEG antibody-mediated complement activation differentially shapes the cutaneous distribution dynamics and spatial accumulation patterns of liposomal drugs across species. Strikingly, mice exhibited increased skin accumulation and toxicity in the presence of anti-PEG antibody, whereas rats showed reduced cutaneous exposure due to predominant hepatic-splenic clearance. Collectively, our findings suggested that interspecies physiological variabilities determine the <em>in vivo</em> fate of sLip and provided mechanistic insights for predicting and mitigating liposomal toxicities in translational settings.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 7001-7018"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances and perspectives of next-generation antitumor antibody-based modalities: Structural innovation and target-driven strategies 新一代抗肿瘤抗体模式的进展与展望：结构创新和靶标驱动策略

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-06-29 DOI: 10.1016/j.apsb.2026.06.028

Liangjie Sun, Baixin Xu, Shuhang Wang, Ning Li

{"title":"Advances and perspectives of next-generation antitumor antibody-based modalities: Structural innovation and target-driven strategies","authors":"Liangjie Sun, Baixin Xu, Shuhang Wang, Ning Li","doi":"10.1016/j.apsb.2026.06.028","DOIUrl":"10.1016/j.apsb.2026.06.028","url":null,"abstract":"<div><div>Antibody-based therapies have gained significant traction in oncology, as evidenced by their prominent presence at international conferences such as American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). Modalities including antibody–drug conjugates (ADCs), bispecific antibodies (BsAbs), and T-cell engagers (TCEs) are increasingly recognized as pillars of precision medicine. Driven by advances in molecular engineering, antibody formats and mechanisms of action have evolved beyond conventional antigen blockade to encompass multimodal cytotoxicity and immune modulation. ADCs now leverage optimized linkers and payloads for targeted delivery and potent tumor cell killing. BsAbs simultaneously engage tumor and immune cell targets to enhance immune activation, while TCEs enable T cells to recognize intracellular antigens presented <em>via</em> MHC, overcoming the limitations of extracellular targeting. Emerging design strategies are increasingly tailored to target-specific features such as expression levels, internalization capacity, and cellular subtype. Innovations include non-internalizing ADCs for low-abundance targets and biased antibody architectures that preferentially activate CD8<sup>+</sup> T cells. These developments are expanding the therapeutic landscape toward greater efficacy, safety, and personalization. This review outlines the global landscape of antibody drug development, highlighting a paradigm shift toward target-driven design principles that integrate structural innovation with functional precision.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6507-6525"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis 通过靶向纳米免疫治疗动脉粥样硬化重塑巨噬细胞efferocytosis和表型

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-08-08 DOI: 10.1016/j.apsb.2026.08.006

Zhongshan He, Yaoyao Luo, Yongjiang Li, Shuping Yang, Yingjun Fan, Yi Zhang, Shengbin Liu, Zhuoming Zhou, Chengjian Cao, Haixing Shi, Mengran Guo, Yuting Chen, Yupei Zhang, Duotian Qin, Wei Chen, Xiangrong Song

{"title":"Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis","authors":"Zhongshan He, Yaoyao Luo, Yongjiang Li, Shuping Yang, Yingjun Fan, Yi Zhang, Shengbin Liu, Zhuoming Zhou, Chengjian Cao, Haixing Shi, Mengran Guo, Yuting Chen, Yupei Zhang, Duotian Qin, Wei Chen, Xiangrong Song","doi":"10.1016/j.apsb.2026.08.006","DOIUrl":"10.1016/j.apsb.2026.08.006","url":null,"abstract":"<div><div>Macrophages within advanced atherosclerotic lesions typically exhibit impaired efferocytosis and tend to adopt a pro-inflammatory M1-like phenotype, leading to the progression of atherosclerosis. Despite this challenge, the development of biocompatible nanotherapeutics capable of effectively remodeling macrophage efferocytosis and phenotype remains elusive. Here, we developed engineered targeted-peptide-modified nanocarriers (PP) and demonstrated their potential to restore macrophage efferocytosis while promoting re-polarization towards an anti-inflammatory M2-like phenotype. Furthermore, PP efficiently facilitated the delivery of an inflammation-resolving-drug to lesional macrophages within advanced atherosclerotic lesions. This combination approach substantially enhanced the anti-atherosclerotic efficacy of PP-based nanomedicine, effectively ameliorating atherosclerosis progression. In advanced plaque-bearing <em>ApoE</em><sup>−/−</sup> mice, PP nanomedcine efficiently accumulated in atherosclerotic plaques, notably restoring macrophage efferocytosis, promoting anti-inflammatory M2-like macrophage polarization, and leading to reduced plaque areas and enhanced plaque stability. This study not only underscores the new pleiotropic effects of PP to restore macrophage efferocytosis and modulate macrophage phenotype, but also highlights the promising potential of PP for the treatment of atherosclerosis and diseases associated with macrophage dysfunction.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6984-7000"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery of a small molecule RIOK1 inhibitor CINS-1 against colorectal cancer via disrupting ribosomal biosynthesis 小分子RIOK1抑制剂CINS-1通过破坏核糖体生物合成来对抗结直肠癌的发现

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-07-08 DOI: 10.1016/j.apsb.2026.07.004

Ying Jiang, Chuan Huang, Fang Wu, Guolong Liu, Shanhe Wan, Yongxin Chen, Ruohong Yan, Zichao Yang, Yuanxin Tian, Tingting Zhang, Xiaoyun Wu, Le Yu, Shaoyu Wu, Shuwen Liu, Jianjun Chen, Wei Xu, Jiajie Zhang

{"title":"Discovery of a small molecule RIOK1 inhibitor CINS-1 against colorectal cancer via disrupting ribosomal biosynthesis","authors":"Ying Jiang, Chuan Huang, Fang Wu, Guolong Liu, Shanhe Wan, Yongxin Chen, Ruohong Yan, Zichao Yang, Yuanxin Tian, Tingting Zhang, Xiaoyun Wu, Le Yu, Shaoyu Wu, Shuwen Liu, Jianjun Chen, Wei Xu, Jiajie Zhang","doi":"10.1016/j.apsb.2026.07.004","DOIUrl":"10.1016/j.apsb.2026.07.004","url":null,"abstract":"<div><div>Colorectal cancer (CRC) remains one of the most prevalent malignancies globally. Despite significant advancements in targeted therapies, drug resistance and therapeutic target mutations continue to pose challenges. Consequently, identifying novel therapeutic targets and developing related compounds are essential for discovering new CRC treatment strategies. The RIO Kinase 1 (RIOK1) protein has emerged as a potential anti-tumor target, playing a critical role in eukaryotic ribosomal biosynthesis and modulating cellular proliferation. However, few compounds have been designed to target RIOK1, and the antitumor activity of RIOK1 inhibitors has yet to be thoroughly investigated. In this study, we report the optimization of pyridine caffeic acid benzyl amide derivatives as RIOK1 inhibitors and identified CINS-1 as a potent compound with markedly enhanced binding affinity for AfRIOK1 and RIOK1. Notably, we elucidated the crystal structure of AfRIOK1 in complex with CINS-1. Our findings further confirm the inhibitory effects of CINS-1 on CRC cell proliferation both <em>in vitro</em> and <em>in vivo</em>. Additionally, CINS-1 was shown to disrupt ribosomal biosynthesis by hindering 18S maturation and triggering a P53-mediated nucleolar stress response. Overall, these results provide a theoretical and empirical basis for considering the RIOK1 inhibitor CINS-1 as a promising candidate for anti-CRC therapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6831-6851"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antihypertensive drug-induced liver injury is rare, but strongly associated with HLA-B∗35:01 抗高血压药物引起的肝损伤是罕见的，但与HLA-B * 35:01密切相关

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-06-10 DOI: 10.1016/j.apsb.2026.06.003

Lily Dara, Paola Nicoletti, Chaudry Nasir Majeed, Andrew Dellinger, David E. Kleiner, Mahmoud G. Mohamed, Tatyana Kushner, Raj Vuppalanchi, Elizabeth J Phillips, David A. Ostrov, Mohammed Umair Masood, Huiman Barnhart, Jiezhun Gu, Herbert L. Bonkovsky

{"title":"Antihypertensive drug-induced liver injury is rare, but strongly associated with HLA-B∗35:01","authors":"Lily Dara, Paola Nicoletti, Chaudry Nasir Majeed, Andrew Dellinger, David E. Kleiner, Mahmoud G. Mohamed, Tatyana Kushner, Raj Vuppalanchi, Elizabeth J Phillips, David A. Ostrov, Mohammed Umair Masood, Huiman Barnhart, Jiezhun Gu, Herbert L. Bonkovsky","doi":"10.1016/j.apsb.2026.06.003","DOIUrl":"10.1016/j.apsb.2026.06.003","url":null,"abstract":"<div><div>Anti-hypertensive (anti-HTN) drugs are widely prescribed, but the features of associated drug-induced liver injury (DILI) are poorly defined. A total of 2207 patients enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2003 to 2024 were adjudicated as definite, highly likely, or probable DILI. Of these, 44 cases were attributed to anti-HTN drugs. These were compared with non-anti-HTN DILI cases and population controls. Human Leukocyte Antigen (HLA) sequencing was performed, and allele frequencies were analyzed using Fisher’s Exact Test. Among the 44 anti-HTN DILI cases, 14 were caused by ACE inhibitors/ARBs, 13 by methyldopa, 11 by hydralazine, and 3 each by beta-blockers and calcium-channel blockers. Methyldopa DILI presented with hepatocellular injury in young women (prescribed mainly for pregnancy-related HTN). Non-methyldopa cases were 60% hepatocellular, 28% cholestatic, and 9% mixed. Severe outcomes included two liver transplants and two deaths (lisinopril and hydralazine). HLA-B∗35:01 was markedly enriched (50% <em>vs.</em> 13% in controls; OR 6.0; <em>P</em> = 1 × 10<sup>−8</sup>) and was linked to shorter latency (50 <em>vs.</em> 109 days; <em>P</em> = 0.02) but not severity. HLA-B∗35:01 was overrepresented across all drug classes, including 66% of methyldopa cases, 27% of hydralazine cases, and 42% of ACE/ARB cases. DILI from anti-HTN medications is very rare but strongly associated with HLA-B∗35:01, especially for methyldopa. Carriers display a shorter latency, potentially indicating an accelerated adaptive immune response, that warrants further exploration.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6676-6685"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cover Story 封面故事

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-10-16 DOI: 10.1016/S2211-3835(26)00573-3

引用次数: 0

The interaction of flavonoids, alkaloids, and terpenoids with the major drug transporters in the organic anion transporting polypeptide and organic anion transporter families 类黄酮、生物碱和萜类化合物与有机阴离子转运多肽和有机阴离子转运家族中主要药物转运体的相互作用

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-07-25 DOI: 10.1016/j.apsb.2026.07.032

Zichong Li, Xuyang Wang, Chaomin Pan, Mei Hong

{"title":"The interaction of flavonoids, alkaloids, and terpenoids with the major drug transporters in the organic anion transporting polypeptide and organic anion transporter families","authors":"Zichong Li, Xuyang Wang, Chaomin Pan, Mei Hong","doi":"10.1016/j.apsb.2026.07.032","DOIUrl":"10.1016/j.apsb.2026.07.032","url":null,"abstract":"<div><div>Natural compounds are ubiquitously found in the plant kingdom and are well-known for their beneficial effects on human health. The easy accessibility and the relatively affordable price make them popular choices for self-medication and/or as part of a healthy daily diet. While it has long been established that natural compounds can influence the function of drug transporters, information about these interactions is often scattered and fragmented. To more systematically and comprehensively summarize the available information in the related field, we categorized the natural products that affect uptake transporters in the organic anion transporting polypeptide (OATP) and organic anion transporter (OAT) families into three groups: flavonoids, alkaloids, and terpenoids. By providing the half-maximal inhibitory concentration (IC<sub>50)</sub> and/or inhibition constant (<em>K</em><sub>i</sub>) of the specific substrates and comparing them to the maximum plasma concentrations (<em>C</em><sub>max</sub>) of natural products, the likelihood of drug–drug interactions (DDIs) at these transporters is proposed. Moreover, information regarding mechanistic studies, which is essential for understanding the molecular mechanisms of natural product–transporter interactions but is currently quite limited, is included. We also suggested potential indirect DDIs posed by natural compounds that are mediated by nuclear receptors and protein kinases, which may affect expression and post-translational modification of OATPs and OATs.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6395-6431"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping neutrophil membrane bioactivity to therapeutic interfaces: Biology, disease targeting, and activity-guided biomimetic therapy 将中性粒细胞膜生物活性映射到治疗界面：生物学、疾病靶向和活动引导的仿生治疗

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-08-26 DOI: 10.1016/j.apsb.2026.08.013

Qingqing Yang, Mingjing Leng, Wenbi Jiang, Huan Yang, Tong Wu, Ting Zhou, Zhennan She, Gang Xiang, Xing Zhou, Xiaohui Li

{"title":"Mapping neutrophil membrane bioactivity to therapeutic interfaces: Biology, disease targeting, and activity-guided biomimetic therapy","authors":"Qingqing Yang, Mingjing Leng, Wenbi Jiang, Huan Yang, Tong Wu, Ting Zhou, Zhennan She, Gang Xiang, Xing Zhou, Xiaohui Li","doi":"10.1016/j.apsb.2026.08.013","DOIUrl":"10.1016/j.apsb.2026.08.013","url":null,"abstract":"<div><div>Neutrophil plasma membranes encode a tightly coordinated set of bioactivities that control inflammatory trafficking, endothelial adhesion under shear, effector activation, and immune regulation. In this review, we present a membrane-centric framework that conceptualizes the neutrophil membrane as a programmable therapeutic interface integrating targeting, adhesion, and effector regulation. We delineate core membrane modules—including chemokine-sensing G protein-coupled receptors (GPCRs), selectin ligands, <em>β</em>2 integrins, Fc<em>γ</em> and complement receptors, pattern-recognition receptors (PRRs), and lipid-raft microdomains—and examine how their coordinated dynamics govern tissue targeting, adhesion kinetics, effector thresholds, and resolution. Integrating evidence from infection, sterile inflammation, autoimmunity, and cancer, we highlight how dysregulated membrane programs drive pathology, while their selective tuning enables therapeutic benefit. Building on this biology, we discuss two convergent intervention strategies: direct pharmacological modulation of neutrophil membrane signaling axes, and activity-guided engineering of neutrophil membrane-derived therapeutics, including native vesicles and membrane-coated nanomaterials. We further link key engineering parameters—such as membrane orientation, ligand density, glycan architecture, and microdomain integrity—to mechanism-based potency, safety, and translational control. By positioning the neutrophil membrane as a programmable interface rather than a static biomimetic shell, this review outlines a rational roadmap for developing predictable, dose-controlled therapies for infection, inflammatory diseases, and cancer.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6574-6605"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0